Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmacology,Genetics,Biochemistry
Link
http://link.springer.com/article/10.1007/s40495-018-0122-9/fulltext.html
Reference104 articles.
1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–27. https://doi.org/10.1038/nri2744 .
2. Eiermann W, International Herceptin Study G. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12(Suppl 1):S57–62. https://doi.org/10.1093/annonc/12.suppl_1.S57 .
3. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol. 2002;3(3):137–44. https://doi.org/10.1016/S1470-2045(02)00676-9 .
4. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154–69. https://doi.org/10.1097/PPO.0b013e318172d704 .
5. •• Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. https://doi.org/10.1038/nrd.2016.268 . This article provides a up-to-date review of current progress in ADCs and discussed strategies for the new waves of ADCs.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?;Journal of Medicinal Chemistry;2024-07-09
2. What are the challenges involved in the strategies for future antibody-drug conjugate discovery and development for oncology?;Expert Opinion on Drug Discovery;2023-04-23
3. The Future of Antibody Drug Conjugation by Comparing Various Methods of Site-Specific Conjugation;Discovery Medicine;2023
4. Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population;Pediatric Drugs;2022-10-06
5. Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function;Toxicologic Pathology;2022-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3